Multiple Sclerosis
Feature
Twelve medical groups pen letter opposing UHC copay accumulator program
“We see policies like this as sacrificing patients to the battle over high drug prices,” said Dr. Christopher Phillips.
Expert Commentary
When Female Patients with MS Ask About Breastfeeding, Here’s What to Tell Them
Chances are your female patients of child-bearing age with multiple sclerosis—particularly if they become...
Conference Coverage
Newer DMTs are more effective than injectable DMTs in pediatric MS
A retrospective study suggests that the safety and tolerability of newer disease-modifying therapies are the same in children as in adults.
Conference Coverage
Neutrophil granulocyte markers may distinguish between demyelinating diseases
Evaluating CSF for neutrophil granulocyte markers may help distinguish between MS, neuromyelitis optica spectrum disorders, and anti–myelin...
Conference Coverage
NMOSD challenges in children
Neuroimmunologists discuss key diagnosis and treatment strategies.
Expert Commentary
ICYMI: MSVirtual2020 Virtual Joint ACTRIMS-ECTRIMS Meeting Summary
I had the privilege of attending and speaking at the recent MS Virtual 2020—the 8th Joint ACTRIMS-...
Conference Coverage
Highlights on Treatment of Progressive MS From ECTRIMS 2020
Dr Mark Freedman reports on key findings in progressive MS from ECTRIMS 2020, including use of first-in-class TKI...
Conference Recap
ECTRIMS 2020 Highlights: Managing RRMS, Symptoms in the Time of COVID-19
Dr Mark Freedman discusses new data on managing fatigue in patients with RRMS and highlights guidelines for RRMS treatment during the COVID-19...
Conference Recap
Biomarkers for Disease Activity in RRMS Reported at ACTRIMS/ECTRIMS 2020
Dr Tobias Derfuss reviews data indicating that serum neurofilament is a clinically useful biomarker of disease activity in RRMS, as reported at...
Conference Coverage
Bacteria may be associated with risk of MS relapse
A study of patients with pediatric-onset MS suggests that methanogenesis pathways may play a role in the risk of relapse.
Conference Coverage
COVID-19 risks are no higher in patients with multiple sclerosis
MS does not appear to be associated with higher risks of severe COVID-19 outcomes compared with the general population.